Literature DB >> 32030524

Pharmacogenomics of Pain Management: The Impact of Specific Biological Polymorphisms on Drugs and Metabolism.

Elyse M Cornett1, Michelle A Carroll Turpin2, Allison Pinner3, Pankaj Thakur4, Tamizh Selvan Gnana Sekaran5, Harish Siddaiah4, Jasmine Rivas6, Anna Yates7, G Jason Huang8, Anitha Senthil9, Narjeet Khurmi10, Jenna L Miller11, Cain W Stark12, Richard D Urman13, Alan David Kaye14.   

Abstract

PURPOSE OF REVIEW: Pain is multifactorial and complex, often with a genetic component. Pharmacogenomics is a relative new field, which allows for the development of a truly unique and personalized therapeutic approach in the treatment of pain. RECENT
FINDINGS: Until recently, drug mechanisms in humans were determined by testing that drug in a population and calculating response averages. However, some patients will inevitably fall outside of those averages, and it is nearly impossible to predict who those outliers might be. Pharmacogenetics considers a patient's unique genetic information and allows for anticipation of that individual's response to medication. Pharmacogenomic testing is steadily making progress in the management of pain by being able to identify individual differences in the perception of pain and susceptibility and sensitivity to drugs based on genetic markers. This has a huge potential to increase efficacy and reduce the incidence of iatrogenic drug dependence and addiction. The streamlining of relevant polymorphisms of genes encoding receptors, transporters, and drug-metabolizing enzymes influencing the pain phenotype can be an important guide to develop safe new strategies and approaches to personalized pain management. Additionally, some challenges still prevail and preclude adoption of pharmacogenomic testing universally. These include lack of knowledge about pharmacogenomic testing, inadequate standardization of the process of data handling, questionable benefits about the clinical and financial aspects of pharmacogenomic testing-guided therapy, discrepancies in clinical evidence supporting these tests, and doubtful reimbursement of the tests by health insurance agencies.

Entities:  

Keywords:  Genes; Opioids; Pharmacogenetics; Pharmacogenomics; pain management

Mesh:

Substances:

Year:  2020        PMID: 32030524     DOI: 10.1007/s11912-020-0865-4

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN: 1523-3790            Impact factor:   5.075


  162 in total

Review 1.  Opioid genetics: the key to personalized pain control?

Authors:  R Branford; J Droney; J R Ross
Journal:  Clin Genet       Date:  2012-07-27       Impact factor: 4.438

2.  The difference between acute and chronic pain.

Authors:  K P Grichnik; F M Ferrante
Journal:  Mt Sinai J Med       Date:  1991-05

Review 3.  Sex, gender, and pain: women and men really are different.

Authors:  R B Fillingim
Journal:  Curr Rev Pain       Date:  2000

Review 4.  A brief comparison of the pathophysiology of inflammatory versus neuropathic pain.

Authors:  Qinghao Xu; Tony L Yaksh
Journal:  Curr Opin Anaesthesiol       Date:  2011-08       Impact factor: 2.706

Review 5.  Next-Generation Sequencing Strategies.

Authors:  Shawn E Levy; Braden E Boone
Journal:  Cold Spring Harb Perspect Med       Date:  2019-07-01       Impact factor: 6.915

6.  The effect of UGT2B7*2 polymorphism on the pharmacokinetics of OROS® hydromorphone in Taiwanese subjects.

Authors:  Joris Vandenbossche; Henry Richards; Stephan Francke; An Van Den Bergh; Chih Cherng Lu; Monique A Franc
Journal:  J Clin Pharmacol       Date:  2014-04-15       Impact factor: 3.126

7.  Genetic variations associated with red hair color and fear of dental pain, anxiety regarding dental care and avoidance of dental care.

Authors:  Catherine J Binkley; Abbie Beacham; William Neace; Ronald G Gregg; Edwin B Liem; Daniel I Sessler
Journal:  J Am Dent Assoc       Date:  2009-07       Impact factor: 3.634

8.  Case-control association analysis of polymorphisms in the δ-opioid receptor, OPRD1, with cocaine and opioid addicted populations.

Authors:  R C Crist; L M Ambrose-Lanci; M Vaswani; T K Clarke; A Zeng; C Yuan; T N Ferraro; H Hakonarson; K M Kampman; C A Dackis; H M Pettinati; C P O'Brien; D W Oslin; G A Doyle; F W Lohoff; W H Berrettini
Journal:  Drug Alcohol Depend       Date:  2012-07-12       Impact factor: 4.492

9.  Variability of the drug response to nonsteroidal anti-inflammatory drugs according to cyclooxygenase-2 genetic polymorphism.

Authors:  Sook Joung Lee; Min Kyu Park; Dong-Seong Shin; Min Ho Chun
Journal:  Drug Des Devel Ther       Date:  2017-09-13       Impact factor: 4.162

10.  Fentanyl Enhances Hepatotoxicity of Paclitaxel via Inhibition of CYP3A4 and ABCB1 Transport Activity in Mice.

Authors:  Jing-Dun Xie; Yang Huang; Dong-Tai Chen; Jia-Hao Pan; Bing-Tian Bi; Kun-Yao Feng; Wan Huang; Wei-An Zeng
Journal:  PLoS One       Date:  2015-12-03       Impact factor: 3.240

View more
  3 in total

1.  The Role of Pharmacogenomics in Postoperative Pain Management.

Authors:  E Paylor Sachtleben; Kelsey Rooney; Hannah Haddad; Victoria L Lassiegne; Megan Boudreaux; Elyse M Cornett; Alan D Kaye
Journal:  Methods Mol Biol       Date:  2022

2.  Pharmacogenomics of Opioid Treatment for Pain Management.

Authors:  Sarahbeth Howes; Alexandra R Cloutet; Jaeyeon Kweon; Taylor L Powell; Daniel Raza; Elyse M Cornett; Alan D Kaye
Journal:  Methods Mol Biol       Date:  2022

3.  Effects of Dexmedetomidine on the Pharmacokinetics of Parecoxib and Its Metabolite Valdecoxib in Beagles by UPLC-MS/MS.

Authors:  Jie Hu; Bing-Feng Lv; Wen-Jing Guo; Bo-Wen Wang; Di Miao; Xiang-Jun Qiu; Xing-Peng Chen
Journal:  Biomed Res Int       Date:  2020-08-06       Impact factor: 3.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.